Pyrogenicity of hyaluronic acid hydrogel crosslinked by divinyl sulfone for soft tissue augmentation

JinTae Kim, JaeHa Choi, DeukYong Lee

.

DOI: 10.4236/ns.2010.27096                

Abstract

Hyaluronic acid hydrogels (HAHs) were synthesized by immersing the microbeads in phosphate buffered saline solution to assess short term biocompatibility of the gels by means of the rabbit pyrogen test and the bacterial endotoxin test. The rise in body temperature of 3 male New Zealand white rabbits weighing about 2~3 kg (12~16 weeks old) following intravenous injection of the test article (10 mL/kg) was mo nitored at 30 min intervals in 3 h to examine the pyrogenicity. No rabbits showed an individual rise in temperature of 0.5oC or more above its respective control temperature. The temperature rises of the rabbits after injection were 0.12oC, 0.13oC, and 0.18oC, respectively, sugge sting that HAH meets the requirements for the absence of pyrogens. The bacterial endotoxin test revealed that the concentration of endoto xins required to cause the lysate to clot under standard conditions was < 0.125 EU/mL. Comparing the HAHs that was synthesized in this experiment to the ones approved by FDA, the amount of < 0.125 EU/mL endotoxins is relatively safe and effective. The test solution did not contain any interfering factors under the ex perimental conditions used. It is conceivable that the HAHs are likely to be suitable injectable dermal filler for facial soft tissue augmentation due to the absence of pyrogens

Keywords

Hyaluronic Acid Hydrogel; Injectable Dermal Filler; Pryogenicity; Endotoxin; Interfering Factor; Soft Tissue Augmentation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Jeon, O., Song, S.J., Lee, K., Park, M.H., Lee, S., Hahn, S.K., Kim, S. and Kim, B. (2007) Mechanical properties and degradation behaviors of hyaluronic acid hydrogels crosslinked at various crosslinking densities. Carbohy drate Polymers, 70(3), 251257.
[2]	Monheit, G.D. and Coleman, K.M. (2006) Hyaluronic acid fillers. Dermatol Therapy, 19(3), 141150.
[3]	Kim, J.T. and Choi, J.H. (2009) Production and eva luation of hyaluronic acid gel for soft tissue augme ntation. Biomaterials Research, 13(9), 105108.
[4]	Maas, C.S., Papel, I.D., Creene, D. and Stoker, D.A. (1997) Complications of injectable synthetic polymers in facial augmentation. Dermatologic Surgery, 23(10), 871877.
[5]	Hoffmann, C., SchullerPetrovic, S., Soyer, H.P. and Kerl, H. (1999) Adverse reactions after cosmetic lip augmentation with permanent biologically inert implant materials. Journal of the American Academy of Dermatology, 40(1), 100102.
[6]	Narins, R.S., Brandt, F., Leyden, J., Lorenc, Z.P., Rubin, M. and Smith, S. (2003) A randomized, doubleblind, multicenter comparison of the efficacy and tolerability of restylane versus zyplast for the correction of nasolabial folds. Dermatologic Surgery, 29(6), 588595.
[7]	Ramires, P.A., Miccoli, M.A., Panzarini, E., Dini, L. and Protopapa, C. (2005) In Vitro and In Vivo biocompatibility evaluation of a polyalkylimide hydrogel for soft tissue augmentation. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 72B(2), 230238.
[8]	Kogan, G., Soltes, L., Stern, R. and Gemeiner, P. (2007) Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnology Letters, 29(1), 1725.
[9]	Kim, J.T., Kook, C.H. and Choi, J.H. (2009) Production equipment and method of polymer gel for bioimplanting. Journal of Korean Society of Mechanical Technology, 11(2), 8994.
[10]	Ochiai, M., Yamamoto, A., Kataoka, M., Toyoizumi, H., Arakawa, Y. and Horiuchi, Y. (2007) A quantitative in vitro assay to detect biological activity of endotoxin using rabbit peripheral blood. Proceedings of the 6th World Congress on Alternative and Animal Use in the Life Science, 14(3), 641645.
[11]	(2002) European Pharmacopoeia, 4th Edition, Bacterial Endotoxins, 140147.
[12]	http://www.accessdata.fda.gov/cdrh_docs/pdf2/P020023b.pdf
[13]	http://www.accessdata.fda.gov/cdrh_docs/pdf5/P050033b. pdf
[14]	http://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047b. pdf